复旦张江(01349.HK) 公布,由集团研发的盐酸氨酮戊酸颗粒剂,用于非肌层浸润性膀胱癌手术切除辅助的验证性临床研究于近日成功完成首例受试者入组。(ca/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-13 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.